Pharmaceutical stocks are an interesting area to watch as investors look to build watchlists ahead of Muhurat trading. However, the sector enters Samvat 2083 with mixed opportunities. While Indian pharmaceutical companies continue to grow their presence in international markets, there are concerns around pricing pressures in the US, regulatory issues, and rising costs.

Investors will want to see how well companies are managing these to create more value in their businesses. Drug manufacturers with diverse pipelines of products, strong export mix, and good regulatory compliance could be better positioned to see continued earnings growth. CDMOs (Contract Development and Manufacturing Organisation) could also benefit from rising outsourcing by global pharmaceutical firms.

Why Watch Pharma Stocks in Samvat 2083

India’s pharmaceutical industry continues to grow due to strong manufacturing capabilities and increased presence in international markets. In FY26, India’s pharmaceutical exports totalled around $31.13 billion (industry estimate). This is not just about generic drugs. Global pharmaceutical companies are looking to work with manufacturers who can provide them with complex formulations, biologics, speciality products, and research-driven drugs.

This creates opportunities for Indian companies in:

• Complex generics: Creating more complex drugs with less competition.
• Speciality drugs: Creating more differentiated drugs with better pricing.
• Contract manufacturing: Providing research, development, and manufacturing services to global pharmaceutical companies.

India’s pharmaceutical industry could grow revenues by 11-13% in FY27 (CRISIL Ratings); however, this could be offset by rising input, energy, and freight costs. You may want to look at how companies are capitalising on this increased revenue.

US Business: A Key Factor for Pharma Stock Performance

The US is one of the most important markets for Indian manufacturers. However, there can be issues with pricing pressures caused by competition.

Indian companies are facing the following challenges:

• Pricing: Competition from multiple generic manufacturers can cause prices to fall.
• Concentration: Companies with a small number of high-revenue drugs could face volatility in their earnings.
• Regulatory Issues: Issues with US FDA observations, warning letters, and import alerts could delay approvals.
• Trade: Changes to US pharma trade could affect export economics.

However, there are still opportunities in complex generics, speciality drugs, respiratory drugs, and biosimilars. Companies that successfully launch differentiated drugs will reduce their reliance on generic drugs. Investors can look at companies such as Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, and Lupin to see how established Indian drug companies are performing in the US.

Look at how much revenue they are generating in North America, what products they are launching, pricing, and how much of their business is in speciality drugs. Just because they are generating more revenue from the US doesn’t necessarily mean they are generating better profits if prices are falling or marketing costs are rising.

CDMOs: An Opportunity Beyond Generic Drugs

Another area to watch in Samvat 2083 is CDMO. Global pharmaceutical companies often outsource research, development, and manufacturing to specialised partners. This helps with cost management, flexibility, and getting specialist expertise. Indian CDMOs could benefit from this as pharmaceutical companies look to increase diversification.

Some companies/businesses to watch out for are:

• Divi’s Laboratories: Well-placed with a strong presence in pharmaceutical ingredients and custom synthesis.
• Syngene International: Provides research, development, and manufacturing to global pharmaceutical and biotech companies.
• Laurus Labs: Provides CDMO services.

However, look at whether companies have strong manufacturing deals in place.

New Drug Launches and R&D: What Investors Should Track

Research & development plays a key role in the long-term competitiveness of a company. Companies that are heavily reliant on generic drugs may struggle to maintain margins. By creating complex formulations, speciality drugs, & biosimilars, companies can create differentiated portfolios.

As an investor, look at:

• New approvals: How many new products are being approved and how commercial they are.
• Launches: Are companies launching on time or facing delays?
• R&D: Are they spending on research and creating commercially viable products?
• Patents: Are there any patents coming up that could create opportunities for generic manufacturers?
• Differentiated products: Are they launching into markets with little competition?

Companies like Sun Pharma, Dr Reddy’s Laboratories, and Lupin have a strong presence in multiple areas of the pharmaceutical industry. As an investor, look at their pipelines. However, increased R&D doesn’t necessarily mean they have better growth opportunities. Look at the quality of their pipeline, how much they are spending on development, the likelihood of them getting approval, and what return they expect.

Regulatory Observations: A Risk Investors Cannot Ignore

Regulatory compliance is one of the most important factors for pharmaceutical stocks. Indian drug manufacturers supplying to international markets have to comply with strict manufacturing standards.

If they aren’t compliant, this can cause issues with manufacturing, delays to approvals, import alerts, and remediation costs. The US FDA Official Action Indicated (OAI) is a key consideration. In October 2026, industry data shows that around 17.9% of Indian facilities were given an OAI in the US FDA inspections in FY25.

It is always essential to look at:

• FDA inspection results & warning letters.
• Import alerts & manufacturing issues.
• Data integrity & documentation.
• Quality control & manufacturing.
• How long it will take to resolve.

Pharma Stocks to Watch This Diwali 2026

You can build watchlists of companies based on their exposure and growth drivers.

Company	What to track
Sun Pharmaceutical Industries	Speciality medicines, global formulations business, US performance, and regulatory developments
Dr Reddy’s Laboratories	US generics, complex launches, product pipeline, and export growth
Cipla	North American business, respiratory portfolio, and domestic formulations
Lupin	US launches, respiratory products, complex generics, and margin improvement
Aurobindo Pharma	US generics, injectable portfolio, manufacturing compliance, and product launches
Divi’s Laboratories	Custom synthesis, CDMO opportunities, and capacity utilisation
Syngene International	Research outsourcing, manufacturing contracts, and commercialisation pipeline
Laurus Labs	CDMO growth, manufacturing utilisation, and product mix

What Should Investors Check Before Buying Pharma Stocks this Diwali?

While there are many long-term growth opportunities in the pharmaceutical sector, not all companies listed will provide good shareholder returns. Before investing in Muhurat trading stocks, look at the following:

• US revenue: How much revenue they are generating from the US and if they are relying on a few products.
• CDMO: Are they seeing repeat contracts, are they diversified, and are they seeing development turn into manufacturing?
• Regulatory framework: Look at inspection results, outstanding observations, and how they are progressing with remediation at key manufacturing facilities.
• R&D: Compare how much they are spending on research and how many meaningful approvals they have.
• Valuations: Look at the P/E ratio and how this compares to historical valuations, earnings growth, and peers.
• Profitability: Look at operating margins, cash flow, and return ratios. Just because they have higher revenue growth doesn’t mean they have better earnings if manufacturing and compliance costs are increasing.

Bottom line

Pharmaceutical stocks enter Samvat 2083 with opportunities in US generics, speciality drugs, complex launches, and CDMO. However, there could be issues with pricing pressures, regulatory issues, trade, and manufacturing costs. Look at companies with differentiated products, reliable manufacturing, healthy cash flows, and visible growth. Comparing fundamentals and valuations can help you identify sustainable earnings.

Researching pharmaceuticals stocks this Diwali? Visit HDFC SKY MoneyFest for expert stock recommendations, then assess company fundamentals, valuations and risks before investing.